Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation

[1]  J. Shendure,et al.  GRIN2A mutations cause epilepsy-aphasia spectrum disorders , 2013, Nature Genetics.

[2]  Anne de Saint Martin,et al.  GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction , 2013, Nature Genetics.

[3]  U. Stephani,et al.  Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes , 2013, Nature Genetics.

[4]  G. Popescu,et al.  Two serine residues on GluN2A C-terminal tails control NMDA receptor current decay times , 2013, Channels.

[5]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[6]  Shao-Jun Tang,et al.  A Role of the Mammalian Target of Rapamycin (mTOR) in Glutamate-Induced Down-regulation of Tuberous Sclerosis Complex Proteins 2 (TSC2) , 2012, Journal of Molecular Neuroscience.

[7]  D. Meaney,et al.  NR2A and NR2B subunits differentially mediate MAP kinase signaling and mitochondrial morphology following excitotoxic insult , 2012, Neurochemistry International.

[8]  T. Fennell,et al.  Melanoma genome sequencing reveals frequent PREX2 mutations , 2012, Nature.

[9]  Chun-Mei Hu,et al.  Switching of N-methyl-D-aspartate (NMDA) receptor-favorite intracellular signal pathways from ERK1/2 protein to p38 mitogen-activated protein kinase leads to developmental changes in NMDA neurotoxicity. , 2011, The Journal of biological chemistry.

[10]  S. Davis,et al.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.

[11]  H. Ropers,et al.  Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes , 2010, Nature Genetics.

[12]  R. Dingledine,et al.  Glutamate Receptor Ion Channels: Structure, Regulation, and Function , 2010, Pharmacological Reviews.

[13]  A. Lau,et al.  Glutamate receptors, neurotoxicity and neurodegeneration , 2010, Pflügers Archiv - European Journal of Physiology.

[14]  G. Doronzo,et al.  Role of NMDA receptor in homocysteine-induced activation of mitogen-activated protein kinase and phosphatidyl inositol 3-kinase pathways in cultured human vascular smooth muscle cells. , 2010, Thrombosis research.

[15]  Jimmy Lin,et al.  Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 , 2009, Nature Genetics.

[16]  W. Rzeski,et al.  Expression of glutamate receptor subunits in human cancers , 2009, Histochemistry and Cell Biology.

[17]  Chenwei Wang,et al.  Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma , 2009, Nature Genetics.

[18]  C. Moon,et al.  The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth , 2008, Oncogene.

[19]  Jürgen Gallinat,et al.  Molecular Mechanisms of Schizophrenia , 2007, Cellular Physiology and Biochemistry.

[20]  L. Mao,et al.  Regulation of mitogen‐activated protein kinases by glutamate receptors , 2007, Journal of neurochemistry.

[21]  Karin E. Borgmann-Winter,et al.  Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia , 2006, Nature Medicine.

[22]  K. Schlett.  Glutamate as a modulator of embryonic and adult neurogenesis. , 2006, Current topics in medicinal chemistry.

[23]  W. Rzeski,et al.  Glutamate antagonists limit tumor growth. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Takahiro Takano,et al.  Glutamate release promotes growth of malignant gliomas , 2001, Nature Medicine.

[25]  H. Sontheimer,et al.  Glioma cells release excitotoxic concentrations of glutamate. , 1999, Cancer research.

[26]  R. Minchin,et al.  Metabolic activation pathway for the formation of DNA adducts of the carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in rat extrahepatic tissues. , 1994, Carcinogenesis.

[27]  P. Rakic,et al.  Modulation of neuronal migration by NMDA receptors. , 1993, Science.

[28]  Bert Sakmann,et al.  Heteromeric NMDA Receptors: Molecular and Functional Distinction of Subtypes , 1992, Science.

[29]  Xiu-feng Wang,et al.  Baicalin suppresses migration, invasion and metastasis of breast cancer via p38MAPK signaling pathway. , 2013, Anti-cancer agents in medicinal chemistry.

[30]  B. McEwen,et al.  The role of N‐methyl‐D‐asparate receptors in neurogenesis , 2006, Hippocampus.